Skip to main content

Table 1 Veliparib concentrations by LC-MS (left) and its spatial distribution by MALDI (bottom) varies by tissue, drug dose and TNBC cell line of origin

From: Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

  Tissue Amount of tissue
median (RSE)
Comparison Method Subjects (N) Tissues (N) Tissues (N)
<LOD; <LOQ
Median conc.
(RSE %)a
Ion intensity
tumor/muscle (RSE %);
P
a) Veliparib Plasma 50 μL 20 mg/kg
60 mg/kg
LC-MS 9
6
9
6
1; 0
0; 0
0.19 (10)
0.86 (11)
  <0.001 (Low/high dose)
Muscle 49.9 mg (13%) 20 mg/kg
60mg/kg
5
6
5
6
2; 3
1; 1
0.12 (70)
0.47 (47)
  0.882 (Muscle/plasma)*
Liver 49.9 mg (12%) 20 mg/kg
60 mg/kg
6
6
6
6
0; 0
0; 0
0.47 (20)
1.77 (14)
  <0.001 (Liver/plasma)*
TNBC xenograft tissue 46.1 mg (8%) 20 mg/kg
60 mg/kg
12
12
19
17
8; 15
0; 1
0.12 (31)
0.36 (12)
  0.322 (Tumor/plasma)
0.0038 (tumor/plasma)
HCC70 20 mg/kg 4 6 2; 4 0.13 (43)   0.0367 (Cell source)*
60 mg/kg 5 9 0; 0 0.43 (16)
MDA-MB-231 20 mg/kg 4 7 4; 6 0.01 (62)
60 mg/kg 4 5 0; 1 0.27 (18)
MDA-MB-436 20 mg/kg 4 6 2; 5 0.05 (47)
60 mg/kg 3 3 0; 0 0.32 (26)
12 μm section 20 mg/kg
60 mg/kg
MALDI 6
9
6
12
   0.98 (16); 0.02
1.36 (19); 0.13
<0.001 (Low/high dose)
Necrotic tumors
Cellular tumors
15
15
18
18
   1.63 (70%)
1.01 (85%)
0.084 (ROI)*
  1. MALDI matrix-assisted laser desorption/ionization, TBNC triple negative breast cancer, PBMC peripheral blood mononuclear cells, RSE relative standard errors, ROI region of interest, V veliparib
  2. aConcentration (Conc.) of veliparib and carboplatin in mg/L, carboplatin adducts in μmol/g DNA
  3. *P value adjusted for dose